EA201791336A1 - Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk) - Google Patents

Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)

Info

Publication number
EA201791336A1
EA201791336A1 EA201791336A EA201791336A EA201791336A1 EA 201791336 A1 EA201791336 A1 EA 201791336A1 EA 201791336 A EA201791336 A EA 201791336A EA 201791336 A EA201791336 A EA 201791336A EA 201791336 A1 EA201791336 A1 EA 201791336A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tropomyosin
trk
pharmaceutical compositions
compositions based
pharmaceutical formulations
Prior art date
Application number
EA201791336A
Other languages
English (en)
Russian (ru)
Inventor
Харви Либерман
Дунлай Ян
К. Майкл Филбрук
Майкл Сантос
Крис Хо
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55080206&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA201791336(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of EA201791336A1 publication Critical patent/EA201791336A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
EA201791336A 2014-12-18 2015-12-17 Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk) EA201791336A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462093801P 2014-12-18 2014-12-18
PCT/US2015/066396 WO2016100677A2 (en) 2014-12-18 2015-12-17 Pharmaceutical formulations of tropomyosin related kinase (trk) inhibitors

Publications (1)

Publication Number Publication Date
EA201791336A1 true EA201791336A1 (ru) 2017-10-31

Family

ID=55080206

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791336A EA201791336A1 (ru) 2014-12-18 2015-12-17 Фармацевтические составы на основе ингибиторов тропомиозин-родственных киназ (trk)

Country Status (22)

Country Link
US (4) US10219998B2 (cg-RX-API-DMAC10.html)
EP (1) EP3233057A2 (cg-RX-API-DMAC10.html)
JP (1) JP6606183B2 (cg-RX-API-DMAC10.html)
KR (1) KR102561692B1 (cg-RX-API-DMAC10.html)
CN (2) CN107231803B (cg-RX-API-DMAC10.html)
AR (1) AR103176A1 (cg-RX-API-DMAC10.html)
AU (1) AU2015364557C1 (cg-RX-API-DMAC10.html)
BR (1) BR112017012566B1 (cg-RX-API-DMAC10.html)
CA (1) CA2970938C (cg-RX-API-DMAC10.html)
CL (1) CL2017001543A1 (cg-RX-API-DMAC10.html)
CO (1) CO2017007118A2 (cg-RX-API-DMAC10.html)
EA (1) EA201791336A1 (cg-RX-API-DMAC10.html)
IL (1) IL252901B (cg-RX-API-DMAC10.html)
MA (1) MA40698A3 (cg-RX-API-DMAC10.html)
MX (2) MX387694B (cg-RX-API-DMAC10.html)
MY (1) MY195799A (cg-RX-API-DMAC10.html)
NZ (1) NZ733825A (cg-RX-API-DMAC10.html)
PH (1) PH12017501121A1 (cg-RX-API-DMAC10.html)
SG (1) SG11201704872RA (cg-RX-API-DMAC10.html)
TN (1) TN2017000234A1 (cg-RX-API-DMAC10.html)
TW (2) TWI696621B (cg-RX-API-DMAC10.html)
WO (1) WO2016100677A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
MA40698A3 (fr) 2014-12-18 2020-01-31 Genzyme Corp Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk)
CR20180109A (es) 2015-07-20 2018-05-03 Genzyme Corp Inhibidores de receptor del factor estimulador de colonias 1 (csf-1r)
CN110156813B (zh) * 2018-02-13 2023-07-25 北京诺诚健华医药科技有限公司 作为trk抑制剂的杂环化合物
AR114110A1 (es) 2018-02-28 2020-07-22 Lilly Co Eli Anticuerpo anti-trka
EP4180428A1 (en) * 2021-11-12 2023-05-17 Genzyme Corporation Crystalline imidazo[4,5-b]pyridine compound, pharmaceutical compositions, and their use in treating medical conditions
JP2025503380A (ja) * 2022-01-14 2025-02-04 ダイメリックス バイオサイエンス ピーティーワイ リミテッド ケモカインレセプター経路インヒビターを含む組成物
CN114712365B (zh) * 2022-06-07 2022-08-23 山东绿叶制药有限公司 Trk抑制剂在制备治疗迟发性运动障碍药物中的应用
AU2024273547A1 (en) * 2023-05-17 2025-12-04 Centrexion Therapeutics Corporation PARTICLES OF IMIDAZO [4,5-b] PYRIDINE COMPOUND, PHARMACEUTICAL COMPOSITIONS, AND THEIR USE IN TREATING MEDICAL CONDITIONS

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4612323A (en) 1983-06-27 1986-09-16 Sumitomo Chemical Company, Limited Insecticidal and acaricidal derivatives of 1-benzylbenzimidazole
JPS60158180A (ja) 1984-01-30 1985-08-19 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体、その製造法およびそれを有効成分とする殺虫、殺ダニ剤
JPS6117569A (ja) 1984-07-03 1986-01-25 Sumitomo Chem Co Ltd ベンズイミダゾ−ル誘導体およびそれを有効成分とする殺ダニ剤
JPS6117569U (ja) 1984-07-05 1986-02-01 エヌオーケー株式会社 バルブ装置
JPS61151176A (ja) 1984-12-24 1986-07-09 Sumitomo Chem Co Ltd ベンズイミダゾール誘導体およびそれを有効成分とする殺虫、殺ダニ剤
DE4219534A1 (de) 1992-02-19 1993-12-16 Thomae Gmbh Dr K Substituierte Biphenylylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DK154092D0 (da) 1992-12-23 1992-12-23 Neurosearch As Imidazolforbindelser, deres fremstilling og anvendelse
US5702637A (en) 1995-04-19 1997-12-30 Minnesota Mining And Manufacturing Company Liquid crystal compounds having a chiral fluorinated terminal portion
WO1999000372A1 (fr) 1997-06-27 1999-01-07 Fujisawa Pharmaceutical Co., Ltd. Sulfamides et leur utilisation medicale
JP2002507996A (ja) 1997-07-03 2002-03-12 デュポン ファーマシューティカルズ カンパニー 神経学的障害を治療するためのイミダゾピリミジン類およびイミダゾピリジン類
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
US7030150B2 (en) 2001-05-11 2006-04-18 Trimeris, Inc. Benzimidazole compounds and antiviral uses thereof
MXPA04001253A (es) 2001-08-09 2004-06-03 Ono Pharmaceutical Co Derivados de acidos carboxilicos y agente farmaceutico que comprende los mismos como ingrediente activo.
GB0122190D0 (en) 2001-09-14 2001-10-31 Qinetiq Ltd Novel compounds
US20040002145A1 (en) 2002-03-18 2004-01-01 Shewchuk Lisa Marie Crystal structure of liganded cFMS kinase domain
WO2003099276A1 (en) 2002-05-10 2003-12-04 Bristol-Myers Squibb Company 1,1-disubstituted cycloalkyl derivatives as factor xa inhibitors
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
US20070185197A1 (en) 2004-03-31 2007-08-09 Hideki Fujikura Phenol derivative, medicinal composition containing the same, and medicinal use thereof
AP2353A (en) 2004-05-07 2012-02-16 Warner Lambert Co 3- or 4-monosubstituted phenol and thiophenol derivatives useful as H3 ligands.
EP1836182A2 (en) 2004-11-18 2007-09-26 The Institutes for Pharmaceutical Discovery, LLC Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors
KR101362621B1 (ko) 2005-02-16 2014-02-13 아스트라제네카 아베 화합물
JP2006273879A (ja) 2005-03-25 2006-10-12 Fuji Photo Film Co Ltd カラー表示素子及びカラー表示方法
JP4990783B2 (ja) 2005-09-30 2012-08-01 Ｍｓｄ株式会社 ２−ヘテロアリール置換インドール誘導体
CN1947717B (zh) 2005-10-14 2012-09-26 卓敏 选择性抑制腺苷酸环化酶1的化合物在制备用于治疗神经性疼痛和炎性疼痛的药物中的应用
US7851484B2 (en) 2007-03-30 2010-12-14 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
CN101679429A (zh) * 2007-04-18 2010-03-24 阿斯利康(瑞典)有限公司 5-氨基吡唑-3-基-3h-咪唑并[4,5-b]吡啶衍生物及其治疗癌的用途
WO2009026720A1 (en) 2007-08-29 2009-03-05 Methylgene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
WO2010088518A2 (en) 2009-01-31 2010-08-05 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP5759471B2 (ja) 2009-10-29 2015-08-05 ヴェクチュラ リミテッド Ｊａｋ３キナーゼ阻害剤としての窒素含有ヘテロアリール誘導体
WO2011058139A1 (en) 2009-11-12 2011-05-19 Selvita Sp. Z O. O. A compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
US8604217B2 (en) 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
CA2803448A1 (en) 2010-07-06 2012-01-12 Universite De Montreal Imidazopyridine, imidazopyrimidine and imidazopyrazine derivatives as melanocortin-4 receptor modulators
EP2694509B1 (en) 2011-04-05 2016-05-18 Pfizer Limited Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of tropomyosin-related kinases
KR20140105508A (ko) 2011-12-12 2014-09-01 닥터 레디스 레보러터리즈 리미티드 트로포미오신 수용체 키나제(Trk) 억제제인 치환된 피라졸로[1,5-a]피리딘
WO2013176970A1 (en) * 2012-05-22 2013-11-28 Merck Sharp & Dohme Corp. TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
JP6117569B2 (ja) 2013-02-28 2017-04-19 三甲株式会社 ボックスパレット
GB201321741D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9067914B1 (en) 2013-12-10 2015-06-30 Genzyme Corporation Tropomyosin-related kinase (TRK) inhibitors
MA40698A3 (fr) 2014-12-18 2020-01-31 Genzyme Corp Formulations pharmaceutiques d'inhibiteurs de kinase associée à la tropomyosine (trk)
CN107197528B (zh) 2016-03-14 2020-12-25 华为技术有限公司 一种资源调度和分配的方法和装置

Also Published As

Publication number Publication date
CA2970938C (en) 2023-04-18
WO2016100677A3 (en) 2016-08-11
WO2016100677A2 (en) 2016-06-23
US10219998B2 (en) 2019-03-05
BR112017012566B1 (pt) 2024-01-30
CN110950862A (zh) 2020-04-03
MA40698A2 (fr) 2018-10-31
KR20170096160A (ko) 2017-08-23
PH12017501121B1 (en) 2017-11-27
TWI780438B (zh) 2022-10-11
MX2017008058A (es) 2017-09-28
SG11201704872RA (en) 2017-07-28
IL252901A0 (en) 2017-08-31
KR102561692B1 (ko) 2023-07-28
AU2015364557B2 (en) 2021-04-29
MX2020013015A (es) 2021-02-22
US20180000728A1 (en) 2018-01-04
EP3233057A2 (en) 2017-10-25
JP2018503611A (ja) 2018-02-08
US20240189223A1 (en) 2024-06-13
CA2970938A1 (en) 2016-06-23
JP6606183B2 (ja) 2019-11-13
CL2017001543A1 (es) 2018-03-16
US11793749B2 (en) 2023-10-24
US20200048222A1 (en) 2020-02-13
CO2017007118A2 (es) 2017-08-18
MA40698A3 (fr) 2020-01-31
TW202104225A (zh) 2021-02-01
TW201639837A (zh) 2016-11-16
IL252901B (en) 2020-10-29
CN110950862B (zh) 2024-01-05
NZ733825A (en) 2022-02-25
AU2015364557A1 (en) 2017-08-03
CN107231803B (zh) 2019-12-03
CN107231803A (zh) 2017-10-03
AU2015364557C1 (en) 2021-11-18
MY195799A (en) 2023-02-21
US11110055B2 (en) 2021-09-07
BR112017012566A2 (pt) 2018-01-02
PH12017501121A1 (en) 2017-11-27
US20220110861A1 (en) 2022-04-14
TWI696621B (zh) 2020-06-21
MX387694B (es) 2025-03-18
US12527737B2 (en) 2026-01-20
AR103176A1 (es) 2017-04-19
TN2017000234A1 (en) 2018-10-19

Similar Documents

Publication Publication Date Title
MX387694B (es) Formulaciones farmaceuticas de inhibidores de cinasa relacionada con tropomiosina (trk).
EA201791066A1 (ru) Твердые формы ингибитора ask1
PE20171307A1 (es) Compuestos de triazolopirimidina y usos de los mismos
PE20161292A1 (es) Compuestos de nicotinamida sustituida con heteroarilo
WO2016142855A3 (en) Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors
CO2018002829A2 (es) Derivados de 8-[6-[3-(amino)propoxi]-3-piridil]1-isopropilimidazo[4,5-c]quinolin-2-ona como moduladores selectivos de la cinasa de la ataxia telangiectasia mutada (atm)
MX355623B (es) Hidrazino-1h-imidazoquinolin-4-aminas y conjugados elaborados a partir de las mismas.
HK1220355A1 (zh) Mk2抑制劑和其用途
EA201591255A1 (ru) ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-РОДСТВЕННЫХ КИНАЗ (JAK)
PH12014502040A1 (en) Heterocyclyl compounds
PH12015502041B1 (en) Heteroaryl compounds and uses thereof
PH12015501955A1 (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
PE20151332A1 (es) Compuestos de azabencimidazol
PH12017501816B1 (en) Azabenzimidazoles and their use as ampa receptor modulators
MX373129B (es) Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas.
PE20160934A1 (es) (aza) piridopirazolopirimidinonas e indazolopirimidinonas como inhibidores de fibrinolisis
MX2016009581A (es) Derivados de 6-fenil- o 6-(piridin-3-il) indazol y metodos de uso.
PH12015502118A1 (en) Pyridin-4-yl derivatives
UA107353C2 (en) Salts of bicyclo-substituted pyrazolon azo derivatives, preparation method and use thereof
MX2015012896A (es) Inhibidores de pirrolo [2,3-b] piridina cdk9 cinasa.
MX374552B (es) Derivados de 2-fenil-3h-imidazo[4,5-b]piridina útiles como inhibidores de actividad de receptor huérfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamífero.
PH12014500859A1 (en) Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
MX2016009621A (es) Derivados de fur0-3-carboxamida y metodos de uso.
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний